Feature Story

Health Center Today, March 3, 2010

Study by Molecular Cardiology and Angiogenesis Lab Published in Circulation

By Carolyn Pennington

Researchers with the Molecular Cardiology and Angiogenesis Lab.

Health Center researchers in the Molecular Cardiology and Angiogenesis Laboratory have demonstrated for the first time that Thioredoxin-1 (Trx1) gene therapy enhances angiogenic signaling and reduces ventricular remodeling in diabetic animal hearts following a heart attack.

The study is published in the current online edition of Circulation, a journal of the American Heart Association.

"For the first time our novel approach of Trx1 gene therapy may prove to be a strategic therapeutic modality in the treatment of diabetes related cardiac failure," says Nilanjana Maulik, professor of surgery and head of the Molecular Cardiology and Angiogenesis Laboratory.

Lab researchers who worked on the study include Samson Mathews Samuel, Mahesh Thirunavukkarasu, SureshVarma Penumathsa, Dr. Srikanth Koneru and Lijun Zhan.